Skip to main content
Frontiers in Public Health logoLink to Frontiers in Public Health
. 2026 Jun 19;14:1903188. doi: 10.3389/fpubh.2026.1903188

Correction: Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system

Jalal Abu Hamida 1,*, Nimer S Alkhatib 2,3, Khawla Abu Hammour 1, Shiraz Halloush 4, Amanj Kurdi 5, Bander Balkhi 6, Osamah M Alfayez 7, Rimal Mousa 1
PMCID: PMC13330711  PMID: 42404960

In the Acknowledgments, the sentence “The authors would like to extend their appreciation to King Saud University for funding this work through the Ongoing Research Funding program (ORF-2026-76)” was erroneously included.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Public Health are provided here courtesy of Frontiers Media SA

RESOURCES